Treatment Pathway
Treatment of Anxiety Disorder
Anxiety disorders are among the most common mental health conditions, characterized by excessive fear, worry, or nervousness that interferes with daily activities. Types include generalized anxiety disorder (GAD), panic disorder, and social anxiety.
APA (American Psychiatric Association)NICE (UK)BAP (British Association for Psychopharmacology)CANMATWFSBP
Managing Anxiety Disorder effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Anxiety Disorder can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Establish accurate diagnosis with standardised rating scales (PHQ-9, GAD-7, YMRS, PANSS)
- ✓SSRIs or SNRIs as first-line for depression, anxiety disorders, OCD, and PTSD
- ✓Lithium or valproate as mood stabilisers in bipolar disorder
- ✓Antipsychotics for schizophrenia; clozapine for treatment-resistant cases
- ✓Psychotherapy (CBT, IPT, DBT) as first-line or adjunct in most psychiatric conditions
What to Do Now
- Learn your personal risk factors for Anxiety Disorder (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Anxiety Disorder
- Use our AI symptom checker to assess whether your symptoms fit an early Anxiety Disorder pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Anxiety Disorder-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Psychotherapy: CBT for depression, anxiety, OCD, PTSD; DBT for borderline PD; ACT for chronic conditions
- •Regular aerobic exercise: 150 min/week — reduces depression scores comparably to antidepressants in mild-moderate MDD
- •Sleep hygiene: critical in depression, bipolar, and anxiety — circadian rhythm stabilisation
- •Alcohol and substance avoidance: major driver of psychiatric deterioration
- •Social support and peer support groups
- •Mindfulness-based cognitive therapy (MBCT) to prevent MDD relapse
- •Crisis planning: safety plan, emergency contacts, medication access
Treatment Goals
🎯Remission: PHQ-9 <5, GAD-7 <5; minimal/no symptoms for ≥2 months
🎯Functional recovery: return to work/study and social functioning
🎯Relapse prevention: maintenance therapy in recurrent disorders
🎯Quality of life improvement — patient-reported outcomes
🎯Safety: minimise suicide risk; substance use recovery
Monitoring Parameters
- ◆Validated symptom scales: PHQ-9 (depression), GAD-7 (anxiety), MADRS, YMRS — at each visit
- ◆Side effect monitoring: weight, metabolic parameters (antipsychotics), thyroid (lithium), LFTs (valproate)
- ◆Lithium levels: 5–7 days after initiation/dose change; then every 3–6 months when stable (target 0.6–1.0 mmol/L)
- ◆ECG: QTc monitoring with antipsychotics (ziprasidone, amisulpride, haloperidol)
- ◆Metabolic syndrome screening: waist circumference, BP, fasting glucose, lipids — annually on antipsychotics
- ◆AIMS for tardive dyskinesia (antipsychotics) — 6-monthly
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Anxiety Disorder — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Anxiety Disorder combined with new relevant symptoms
- ⚠Sudden worsening of Anxiety Disorder symptoms despite established treatment
Escalation Criteria
- →Active suicidal ideation with intent/plan → emergency psychiatric assessment; hospitalisation if risk confirmed
- →Psychotic relapse in schizophrenia → urgent psychiatric review; consider clozapine if ≥2 antipsychotic failures
- →Bipolar manic episode → inpatient; optimise mood stabiliser; antipsychotic augmentation
- →Treatment-resistant depression (≥2 failed SSRI trials) → augmentation (lithium, aripiprazole), referral, TMS/ECT consideration
Special Populations
Pregnancy: SSRIs (sertraline preferred) generally acceptable; avoid paroxetine (cardiac defects); valproate contraindicated; specialist review
Elderly: lower starting doses; risk of QTc prolongation; avoid TCA (anticholinergic); falls risk with sedating agents
Adolescents: black-box warning — monitor for suicidality in first weeks of antidepressant treatment
Intellectual disability: behavioural approaches first-line; medication at lower doses; monitor for hidden side effects
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →